# US 2015/0147276 A1 · Nanotherapeutics for drug targeting

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0147276 A1
- Document ID: US20150147276A1
- Status: Published application
- Kind: A1
- Application number: 14/405,251
- Filed: 2013-06-07
- Published: 2015-05-28
- Earliest claimed: 2012-06-07
- Assignees: President and Fellows of Harvard College
- Applicants: President and Fellows of Harvard College
- Inventors: Donald E. Ingber; Netanel Korin; Mathumai Kanapathipilai; Oktay Uzun; Anne-Laure Papa
- Web page: https://patentgrep.com/patent/US20150147276A1

## CPC

- A61K 47/34: Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers (A61K47/10 takes precedence)
- A61K 9/0009: {involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis}
- A61K 9/5146: {obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides}
- A61K 9/5153: {Polyesters, e.g. poly(lactide-co-glycolide)}
- A61K 38/482: {Serine endopeptidases (3.4.21)}
- A61K 41/13: by ultrasonic waves
- A61K 47/60: the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
- A61K 47/6937: {the polymer being PLGA, PLA or polyglycolic acid}
- A61K 49/225: {Microparticles, microcapsules (gas-filled to be classified in A61K49/223)}
- A61P 7/00: Drugs for disorders of the blood or the extracellular fluid
- A61P 7/02: Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A61P 9/08: Vasodilators for multiple indications
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 9/14: Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 31/04: Antibacterial agents
- A61P 35/00: Antineoplastic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C08G 63/06: derived from hydroxycarboxylic acids
- A61K 48/0041: {the non-active part being polymeric}
- C12Y 304/21068: Tissue plasminogen activator (3.4.21.68), i.e. tPA
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C08G: MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C12Y: ENZYMES

## Abstract

The invention provides compositions and methods for targeted controlled drug release. The compositions and methods can be used for treating or imaging vascular stenosis, stenotic lesions, occluded lumens, embolic phenomena, thrombotic disorders and internal hemorrhage.

## Claims

### Claim 1

An aggregate comprising a plurality of nanoparticles, wherein the aggregate disaggregates under a predetermined stimulus selected from the group consisting of ultrasound, mechanical strain, vibration, magnetic field, radiation, temperature, ionic strength, pH, pressure, turbulence, change in flow, flow rate, or chemical or enzymatic activation.

### Claim at position 2

2-81. (canceled)

### Claim 82 (depends on 1)

The aggregate of claim 1, wherein the aggregate further comprises a molecule selected from the group consisting of small or large organic or inorganic molecules; carbon-based materials; metals; metal oxides; complexes comprising metals; inorganic nanoparticles; metal nanoparticles; monosaccharides; disaccharides; trisaccharides; oligosaccharides; polysaccharides; glycosaminoglycans; biological macromolecules; enzymes; amino acids; peptides; proteins; peptide analogs and derivatives thereof; peptidomimetics; antibodies and portions or fragments thereof; lipids; carbohydrates; nucleic acids; polynucleotides; oligonucleotides; genes; genes including control and termination regions; self-replicating systems; nucleic acid analogs and derivatives; an extract made from biological materials; naturally occurring or synthetic compositions; or any combinations thereof.

### Claim 83 (depends on 2)

The aggregate of claim 2, wherein the molecule is absorbed/adsorbed on the surface of the aggregate or the nanoparticle constituent of the aggregate.

### Claim 84 (depends on 2)

The aggregate of claim 2, wherein the molecule is encapsulated in the aggregate or the nanoparticle constituent of the aggregate.

### Claim 85 (depends on 2)

The aggregate of claim 2, wherein the molecule is covalently linked to the aggregate or the nanoparticle constituent of the aggregate.

### Claim 86 (depends on 2)

The aggregate of claim 2, wherein the aggregate or the nanoparticle constituent of the aggregate comprises a surface reactive group for linking with the molecule.

### Claim 87 (depends on 2)

The aggregate of claim 2, wherein the molecule is biologically active.

### Claim 88 (depends on 87)

The aggregate of claim 87, wherein the biological activity is selected from the group consisting of adhesive, polymerization, stimulatory, inhibitory, regulatory, trophic, migratory, toxic, or lethal response in a biological assay.

### Claim 89 (depends on 87)

The aggregate of claim 87, wherein the biological activity is selected from the group consisting of exhibiting or modulating an enzymatic activity, blocking or inhibiting a receptor, stimulating a receptor, modulation of expression level of one or more genes, modulation of cell proliferation, modulation of cell division, modulation of cell migration, modulation of cell differentiation, modulation of cell apoptosis, modulation of cell morphology, and any combinations thereof.

### Claim 90 (depends on 87)

The aggregate of claim 87, wherein said biological activity occurs inside a cell.

### Claim 91 (depends on 2)

The aggregate of claim 2, wherein the molecule is a therapeutic agent, or an analog, derivative, prodrug, or a pharmaceutically acceptable salt thereof.

### Claim 92 (depends on 91)

The aggregate of claim 91, wherein the therapeutic agent is an antithrombotic agent, a thrombolytic agent, a thrombogenic agent, an anti-inflammatory agent, anti-atherosclerosis agent, anti-infective agent, anti-sepsis agent, anti-cancer agent, an anti-angiogenesis agent, a pro-angiogenesis agent, a vasodilator, a vasoconstrictor, an anti-neoplastic agent, an anti-proliferative agent, an anti-mitotic agent, an anti-migratory agent, an anti-adhesive agent, an anti-platelet agent, or an anti-polymerization agent.

### Claim 93 (depends on 91)

The aggregate of claim 91, wherein the molecule is a plasminogen activator.

### Claim 94 (depends on 2)

The aggregate of claim 2, wherein the molecule is a targeting ligand.

### Claim 95 (depends on 2)

The aggregate of claim 2, wherein the aggregate comprises both a therapeutic agent and an imaging or contrast agent.

### Claim 96 (depends on 2)

The aggregate of claim 2, wherein the molecule is a prodrug and the aggregate further comprises a reagent for activating the prodrug.

### Claim 97 (depends on 1)

The aggregate of claim 1, wherein the aggregate further comprises an aggregating matrix.

### Claim 98 (depends on 1)

A method of drug delivery to subject, the method comprising administering to the subject an aggregate of claim 1, wherein the aggregate comprises a therapeutic agent; and administering a stimulus to the subject to disaggregate the aggregate and thereby controlling release of the therapeutic agent from the aggregate.

### Claim 99 (depends on 1)

A method of treating or imaging a vascular stenosis and/or a stenotic lesion and/or an embolic or vasoocclusive lesion in a subject, the method comprising administering to a subject in need thereof an aggregate of claim 1.

### Claim 100 (depends on 99)

The method of claim 99, wherein the aggregate is co-administered with a second therapy.

### Claim 101 (depends on 100)

The method of claim 100, wherein the second therapy is an endovascular procedure.

### Claim 102 (depends on 100)

The method of claim 100, wherein the second comprises placement of a wire through an occlusion, mechanical thrombectomy, or administering a therapeutic agent for removing or clearing a blood vessel obstruction.

### Claim 103 (depends on 1)

A method of treating internal hemorrhage in a subject, the method comprising administering to a subject in need thereof an aggregate of claim 1.

### Claim 104 (depends on 1)

A method of theranostic classification in a subject, the method comprising administering to a subject in need thereof an aggregate of claim 1, wherein the aggregate comprises a therapeutic agent and a imaging or contrast agent.
